180 Life Sciences Is Looking To Repurpose Biosimilars
CEO Sets Out Strategy Of Pursuing Novel Indications For Off-Patent Biologics
US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.
